Higher Dose Imatinib for Children With De Novo Chronic Phase Chronic Myelogenous Leukemia: A Report From the Children’s Oncology Group

PURPOSE: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). METHODS: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Autores principales: Champagne, Martin A., Fu, Cecilia H., Chang, Myron, Chen, Helen, Gerbing, Robert B., Alonzo, Todd A., Cooley, Linda D., Heerema, Nyla A., Oehler, Vivian, Wood, Charlotte, French, Mary Ellen, Arceci, Robert J., Smith, Franklin O., Bernstein, Mark L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5157124/
https://ncbi.nlm.nih.gov/pubmed/21465636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23031
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares